NCT06677710 - IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Multiple SclerosisPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)Non-Active Secondary Progressive Multiple SclerosisNon-Active SPMSAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesDemyelinating DiseasesImmune System DiseasesDemyelinating Autoimmune Diseases, Central Nervous System (CNS)

Interventions

DRUG

IDP-023

NK cell therapy

DRUG

Ocrelizumab

Anti-CD20 antibody therapy

DRUG

Interleukin-2

Immune cytokine

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy

DRUG

Mesna

Chemoprotectant

Trial Locations (5)

32803

AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando

63130

Washington University in St. Louis, St Louis

66160

Kansas University Medical Center, Kansas City

80045

University of Colorado Hospital, Aurora

94305

Stanford University, Stanford